Skip to main content
Clinical Trials

Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (CTMS# 18-0005)

Cancer Type

Other Hematopoietic Identifier


Principal Investigator

Ruben Mesa M.D.

For more information about this study
View Details

About This Study

This is a prospective, longitudinal, noninterventional, study in an adult population (patients 18 years) of men and women who have been diagnosed with select subcategories of either MF or ET. Patients will be enrolled over approximately 24 months and observed for a minimum of 36 months from enrollment. Data from usual-care visits will be collected and abstracted into the electronic data capture (EDC) system, approximately every 6 months. At the site s discretion, data may be entered more frequently than every 6 months. Data entry is not required if a usual care visit did not occur.